Supplementary Table S1. Full search strings for each consulted database.

Database	Search strategy
PubMed	**1.** "Warts"[MeSH Terms] **2.** wart[tiab] OR warts[tiab] **3.** "condyloma acuminata"[tiab] OR "condylomata acuminata"[tiab] **4.** 1 OR 2 OR 3 **5.** "Potassium Hydroxide"[MeSH Terms] **6.** KOH[tiab] OR "potassium hydroxide"[tiab] **7.** 5 OR 6 **8.** 4 AND 7
Ovid MEDLINE	**1.** exp Warts/ **2.** exp Condylomata Acuminata/ **3.** (wart* or condyloma acuminata or condylomata acuminata).ti,ab,kf. **4.** or/1-3 **5.** Potassium Hydroxide/ **6.** exp Hydroxides/ **7.** Potassium Compounds/ **8.** (KOH or potassium hydroxide).ti,ab,kf. **9.** or/5-8 **10.** 4 and 9
Google Scholar	"potassium hydroxide" OR KOH warts OR wart OR condylomata
Embase.com	**1.** 'wart'/exp **2.** 'condyloma acuminatum'/exp **3.** wart*:ti,ab,kw OR 'condyloma acuminata':ti,ab,kw OR 'condylomata acuminata':ti,ab,kw **4.** 1 OR 2 OR 3 **5.** 'potassium hydroxide'/exp **6.** koh:ti,ab,kw OR 'potassium hydroxide':ti,ab,kw **7.** 5 OR 6 **8.** 4 AND 7
Scopus	(("Warts" OR "Wart" OR "Condylomata acuminata" OR "Condyloma acuminata") AND ("potassium hydroxide" OR "KOH"))

Supplementary Table S2. Risk of bias assessment and quality of included studies.

	Non-randomized studies[a]		
	Selection	**Comparability**	**Outcome**	**Overall quality**
Al-Hamdi 2012	**	***	*	**M**
Rezk 2017	*	**	*	**L**
Al-Akkam 2018	**	**	*	**M**
Galal 2020	*	**	*	**L**
Alawady 2020	*	**	*	**L**
Loureiro 2008	*	*	*	**L**
Asadi 2016	**	**	*	**M**
Hailou 2021	*	**	*	**L**
Kandil 2016	**	**	*	**M**
Makki 2022	*	*	*	**L**
Hassan 2024	*	**	*	**L**

	Randomized controlled trials[b]							
	1	**2**	**3**	**4**	**5**	**6**	**7**	**Overall risk of bias**
Jayaprasad 2016	**U**	**U**	**H**	**H**	**M**	**L**	**M**	**M**
Yaghoobi 2019	**U**	**U**	**M**	**M**	**L**	**U**	**M**	**M**
Alawady 2022	**U**	**U**	**U**	**U**	**U**	**U**	**H**	**H**
Hanif 2022	**U**	**U**	**H**	**H**	**L**	**U**	**M**	**M**
Bashir 2024	**U**	**U**	**H**	**H**	**L**	**U**	**M**	**M**
Farouk 2025	**U**	**U**	**H**	**L**	**L**	**L**	**M**	**L**
Yaghoobi 2014	**U**	**U**	**H**	**H**	**H**	**U**	**H**	**H**
Camargo 2014	**H**	**H**	**H**	**H**	**H**	**U**	**M**	**H**
Isik 2014	**M**	**U**	**H**	**H**	**U**	**U**	**M**	**M**
Javame Ghazvini 2025	**M**	**U**	**H**	**H**	**L**	**L**	**M**	**M**
Wickremasinghe 2010	**U**	**U**	**H**	**H**	**U**	**U**	**M**	**H**
Elgayar 2025	**U**	**U**	**H**	**L**	**L**	**L**	**M**	**L**
Kalfa 2024	**U**	**U**	**H**	**H**	**U**	**U**	**M**	**H**

L, low; H, high; U, unclear; M, moderate.

[a] Study quality assessment performed by means of Newcastle/Ottawa scale (each asterisk represents if the respective criterion within the subsection was satisfied)

[b] Cochrane Collaboration's tool (Rob1) for assessing the risk of bias across 7 domains: 1 (Random sequence generation), 2 (Allocation concealment), 3 (Blinding of participants and personnel), 4 (Blinding of outcome assessment), 5 (Incomplete outcome data), 6 (Selective reporting) and 7 (Other bias).